文献速递肾移植

肾移植后新发恶性肿瘤

De Novo Malignancies after Kidney Transplantation.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-03-29

综述指出癌症是肾移植后重要结局,多数西方国家为第二死因;移植后癌症风险约为年龄性别匹配普通人群的2-3倍,主要由病毒相关和免疫相关癌症驱动。一旦发生癌症预后 generally 较差,尤其黑色素瘤、肾细胞癌和移植后淋巴增殖性疾病,且高危人群有效筛查和治疗策略有限。

要点

  • 肾移植后癌症风险约为匹配普通人群的2-3倍。
  • 病毒相关和免疫相关癌症是超额风险的主要驱动因素。
  • 黑色素瘤、肾细胞癌和移植后淋巴增殖性疾病预后较差。

核心结论

  • 癌症是肾移植后重要结局,在多数西方国家为第二 leading 死因。
  • 移植后癌症风险约为年龄和性别匹配普通人群的2-3倍。
  • 一旦发生癌症预后 generally 较差,尤其黑色素瘤、肾细胞癌和移植后淋巴增殖性疾病。

研究设计与样本

  • 综述,从患者旅程视角探讨肾移植后癌症的流行病学、负担及筛查治疗策略。

主要发现

  • 移植后癌症超额风险约为年龄和性别匹配普通人群的2-3倍。
  • 超额风险主要由病毒相关和免疫相关癌症驱动。
  • 黑色素瘤、肾细胞癌和移植后淋巴增殖性疾病患者预后尤其差。

临床怎么用

  • 关注肾移植受者的癌症筛查与治疗,尤其病毒相关和免疫相关癌症。
  • 对黑色素瘤、肾细胞癌和移植后淋巴增殖性疾病应重视预后评估。

局限性

  • 综述未提供具体筛查和治疗策略的推荐条款或数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer is an important outcome after kidney transplantation because it is the second leading cause of death in most Western countries. The excess risk of cancer after transplantation is approximately two to three times higher than the age- and sex-matched general population, driven largely by viral- and immune-related cancers. Once cancer develops, outcomes are generally poor, particularly for those with melanoma, renal cell carcinoma, and post-transplant lymphoproliferative disease. More importantly, effective screening and treatment strategies are limited in this high-risk population. In this review, we begin with a patient's journey that maps the experience of living with a kidney transplant and understand the patient's knowledge, education, and experience of cancer in the context of transplantation. The epidemiology and burden of cancer in recipients of kidney transplants, along with the up-to-date screening and treatment strategies, are discussed. We also focus on the current understanding of optimal care for recipients of kidney transplants who are living with cancer from the patients' perspectives.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Al-Adra D, Al-Qaoud T, Fowler K, et al. De Novo Malignancies after Kidney Transplantation. Clin J Am Soc Nephrol. 2021. PMID: 33782034. doi:10.2215/CJN.14570920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。